A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma.

Trial Profile

A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB and IVA Uterine Cervical Carcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2014

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Acronyms CORUS
  • Sponsors Eurofarma
  • Most Recent Events

    • 11 Jul 2014 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 03 May 2013 Actual initiation date changed from Jul 2011 to Jan 2011 as reported by ClinicalTrials.gov.
    • 03 May 2013 Planned End Date changed from 1 Jul 2012 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top